Business Services
Medical
Biotechnology

OncoSec

$0.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0011 (-0.22%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell OncoSec and other stocks, options, ETFs, and crypto commission-free!

About

OncoSec Medical Incorporated Common Stock, also called OncoSec, is a biotechnology company, which engages in designing, developing, and commercializing therapies for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor. Read More The company was founded by Avtar S. Dhillon and Punit S. Dhillon on February 8, 2008 and is headquartered in San Diego, CA.

Employees
34
Headquarters
San Diego, California
Founded
2008
Market Cap
32.38M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.12M
High Today
$0.52
Low Today
$0.48
Open Price
$0.50
Volume
268.31K
52 Week High
$2.21
52 Week Low
$0.423

Collections

Business Services
Medical
Biotechnology
Cancer Prevention
Health
US
North America

News

PR NewswireMar 13

OncoSec to Present at the 31st Annual ROTH Conference

SAN DIEGO and PENNINGTON, N.J., March 13, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that management will present in the 31st Annual ROTH Conference taking place March 17-19, 2019 in Dana Point, CA. The Company's presentation is via webinar and available at http://wsw.com/webcast/roth33/oncs/. About OncoSec Medical Incorporated OncoSec is a clinical-stage biotechnology company focused on developing ...

192
MarketBeatMar 5

Stock Price, News, & Analysis for OncoSec Medical

OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer.

27

Earnings

-$0.31
-$0.25
-$0.19
-$0.13
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Jun 13, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.